Melitidine

Other Names

CAS 1162664-58-5flavanone glycosideMelitidinMelitidinaMélitidinenaringenin-7-O-neohesperidoside-6"-O-(3-hydroxy-3-methylglutaryl)میلیٹیڈن

Synopsis

Melitidin (Melitidin / Melitidine): A Comprehensive Reference

1. Identity: Nomenclature, Source, and Chemical Classification

1.1 Names and Chemical Identity

Melitidin (also spelled melitidine) is a naturally occurring flavonoid glycoside predominantly found in certain varieties of citrus fruits, especially the bergamot orange (Citrus bergamia). It is formally classified as an acylated flavanone glycoside — more specifically, a 3-hydroxy-3-methylglutaryl (HMG) flavonoid glycoside. Its CAS registry number is 1162664-58-5.

The full systematic chemical description identifies melitidin as naringenin 7-(2′′-α-rhamnosyl-6′′-(3′′′′-hydroxy-3′′′′-methylglutaryl)-glucoside), and it was isolated alongside related compounds from the pericarp of Citrus grandis (L.) Osbeck. The compound's key structural feature — a 3-hydroxy-3-methylglutaryl (HMG) moiety esterified to the sugar portion of a flavanone diglycoxide — is responsible for much of its pharmacological interest. The glutaryl derivatives of hesperidin and naringin (brutieridin and melitidin) contain a 3-hydroxy-3-methylglutaryl moiety with a structural similarity to the natural substrate of HMG-CoA reductase (HMGCR) and are likely to exhibit statin-like activity.

Melitidin is closely related to brutieridin, a companion HMG-flavanone glycoside found in the same plant sources. The two compounds are frequently discussed together in scientific literature because of their shared structural motif and overlapping biological properties.

1.2 Botanical Sources

Melitidin was first isolated from Citrus grandis 'Tomentosa', a traditional Chinese medicine used as an antitussive. In this research, melitidin, a flavanone glycoside, was isolated from this species for the first time using chromatographic methods.

Melitidin and its companion compound brutieridin were subsequently quantified in bergamot fruit extracts and identified as structural analogues of statins — lipid concentration-lowering drugs that inhibit HMG-CoA reductase (HMGR).

The bergamot (Citrus bergamia Risso et Poiteau) is a small plant belonging to the Rutaceae family, growing spontaneously on the southern coast of the Calabria region of Italy, where the particular microclimate is ideal for its cultivation. Citrus bergamia Risso is considered a cross between Citrus aurantium L. (sour orange) and Citrus aurantiifolia (Christm.) Swingle (lime) or Citrus limon L. (lemon), although its botanical and geographical origins still remain uncertain.

The bergamot used in cardiovascular research is a specific citrus variety (Citrus bergamia Risso et Poiteau) that grows almost exclusively in the narrow coastal strip of Calabria in southern Italy. The unique soil and microclimate of this region produce a fruit with an unusually rich and diverse polyphenol profile not found in other citrus species.

In addition to pummelo and bergamot, melitidin has also been identified in the pulp of Citrus grandis L. Osbeck (Shatianyu/pummelo), from which a systematic survey of flavonoid composition was conducted. In one study, 11 flavonoids were isolated and identified from pummelo pulp flavonoid extracts (SPFEs), among them 4 previously undescribed flavonoids and 2 firstly isolated from pummelo.

1.3 Commercial Forms and Preparations

Melitidin is not commonly available or sold as an isolated ingredient in the consumer supplement market. Instead, it is typically encountered as part of standardized bergamot polyphenolic fractions (BPF) or bergamot fruit extracts. Bergamot contains specialized flavonoids — brutieridin, melitidin, neoeriocitrin, neohesperidin, and naringin — standardized in modern extracts often called the bergamot polyphenolic fraction. These standardized extracts are available in capsule and tablet form. Due to the poor gastrointestinal absorption of polyphenols, novel formulations have been developed to improve the bioavailability of polyphenol-rich fractions of citrus extracts; standard bergamot polyphenolic fraction (BPF®) as well as a phytosomal formulation (BPF Phyto) have both been investigated.

2. Traditional and Historical Use

2.1 Southern Italian / Mediterranean Tradition

Although melitidin's isolation and identification are relatively recent compared to other botanical compounds, its parent fruit has a long-standing history of medicinal use. Traditional remedies in Southern Italy and the Mediterranean region have utilized bergamot extracts for centuries to promote cardiovascular health, support digestion, and alleviate minor ailments.

Folk healers often prepared infusions and tinctures using bergamot peel and juice, capitalizing on the fruit's rich polyphenolic content — which includes melitidin — to help manage cholesterol and improve overall vitality.

The bergamot is a citrus fruit native to southern Italy with traditional uses that include improving immune response and cardiovascular function. Bergamot juice has long been used in the Calabrian region (the toe of the boot) of Italy as a means to reduce blood lipids.

2.2 Traditional Chinese Medicine

Citrus grandis 'Tomentosa', the cultivated variety of C. grandis (L.) Osbeck grown in Huazhou, Guangdong Province, China, is a famous traditional Chinese medicine recorded in the Pharmacopoeia of the People's Republic of China for preventing cough and dissipating phlegm. Naringin, a component of C. grandis 'Tomentosa', has shown antitussive, anti-inflammatory, antioxidant, and mucous hypersecretion-inhibiting properties, all of which contribute to its cough-preventing reputation.

Melitidin was subsequently identified within this same medicinal plant and shown to contribute independently to the antitussive properties that underpinned the plant's traditional use. This represents the first documented pharmacological rationale for the plant's historical indication as a cough remedy containing melitidin as an active constituent.

2.3 Essential Oil and Cosmetic Use

Considering the high content of volatile compounds, the bergamot peel and many other citrus peels are widely used in the perfume and cosmetic industries. This industrial use is historically distinct from the medicinal-dietary use of bergamot's polyphenol-rich juice and peel extracts, which are the primary vehicle through which melitidin enters the supplement context.

3. Phytochemistry: Key Constituents and Melitidin in Context

3.1 Chemical Structure

Melitidin, a flavanone glycoside, was isolated from Citrus grandis 'Tomentosa' using chromatographic methods, and its structure was confirmed through comprehensive analyses of ultraviolet, infrared, ¹H and ¹³C NMR, HMBC and HMQC spectroscopic, and high-resolution mass spectrometric data. The compound belongs to the flavanone subclass of flavonoids (characterized by the 2,3-dihydro-2-phenylchromen-4-one skeleton) and carries a disaccharide chain (rutinosyl or neohesperidosyl) at the 7-position, with an HMG acid ester on the glucose moiety at the 6′′ position.

The absolute configuration of the HMG fragment in melitidin was assigned to be S through spectroscopic analysis of the mevalonamide obtained by amidation and reduction of the HMG moiety.

3.2 Co-occurring Compounds in Bergamot and Pummelo

Flavone O‐glycosides identified in bergamot include brutieridin, melitidin, rhoifolin 4′-O-glucoside, chrysoeriol 7-O-neohesperidoside-4′-O-glucoside, diosmin, rhoifolin, chrysoeriol 7-O-neohesperidoside, narirutin, and neodiosmin; C-glucoside flavonoids identified in bergamot include apigenin 6,8-di-C-glucoside, diometin 6,8-di-C-glucoside, lucenin‐2, vicenin‐2, stellarin‐2, lucenin‐2‐4′-methyl ether, scoparin, and orientin 4′-methyl ether.

Melitidin, bergamjuicin, and naringin contributed most to ORAC (oxygen radical absorbance capacity) activity in pummelo pulp flavonoid extracts, while bergamjuicin, melitidin and a related acylated glycoside contributed most to cellular antioxidant activity (CAA).

3.3 Biosynthetic Pathway

The acylated flavonoid glycoside melitidin is being developed as an anti-cholesterol statin drug candidate, and a 2023 study described the gene discovery and functional characterization of a new flavonoid gene cluster — comprising UDP-glucuronosyltransferases (CgUGTs), a 1,2-rhamnosyltransferase (Cg1,2RhaT), and acyltransferases (CgATs) — that is responsible for melitidin biosynthesis in pummelo (Citrus grandis (L.) Osbeck).

Population variation analysis indicated that acyltransferases, specific for bitter substrates, mainly determine the natural abundance of melitidin. Co-expression of these clustered genes in Nicotiana benthamiana resulted in the formation of melitidin, demonstrating the potential for metabolic engineering of melitidin in a heterologous plant system. This study established a biosynthetic pathway for melitidin, providing genetic resources for the breeding and genetic improvement of pummelo aimed at fortifying the content of biologically active metabolites.

4. Mechanisms of Action

4.1 HMG-CoA Reductase Modulation

Density functional theory was applied to study the binding mode of melitidin and brutieridin as possible inhibitors of the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) — an enzyme that catalyzes the four-electron reduction of HMG-CoA to mevalonate, the committed step in the biosynthesis of sterols. The two flavonoid conjugates were identified as structural analogues of statins, lipid-concentration-lowering drugs that inhibit HMGR.

The main active compounds in bergamot, such as melitidin and brutieridin, share structural features with the HMG component of statins, which may explain their affinity for HMG-CoA reductase and contribute to their cholesterol-lowering properties.

However, the picture is more nuanced than simple enzyme inhibition. A 2021 cell-culture study published in Nutrients (PMC8469228) challenged the direct HMGCR-inhibition hypothesis: investigators studied bergamot fruit extract (BFE) and its principal components (neoeriocitrin, naringin, neohesperidin, melitidin, and brutieridin) for their ability to regulate cholesterol levels in HepG2 and Caco-2 cells. BFE at increasing concentrations decreased the levels of total and free cholesterol in HepG2 cells, but BFE and its constituents did not directly inhibit HMGCR activity.

In conclusion, BFE and its principal constituents reduce cholesterol through a mechanism that is distinct from direct inhibition of HMG-CoA reductase, as had been suggested by previous laboratory and clinical studies. This is significant as there is now evidence that bergamot fruit extract does not share the same pharmacological mechanism as the cholesterol-lowering drugs known as statins. The cholesterol-lowering effect of BFE appears to be mediated through several mechanisms, including cholesterol biosynthesis modulation in HepG2 cells and cholesterol cellular transport in Caco-2 cells.

As of now, the suggestion that bergamot inhibits HMG-CoA reductase appears to be largely based on molecular modeling and will require further studies to confirm this proposed mechanism of action.

4.2 AMPK Activation

Anti-diabetic and dyslipidemia-correcting effects of bergamot polyphenols may be explained by their ability to activate AMP kinase (AMPK) — a central regulator of glucose and fatty acids metabolism — and to inhibit cAMP phosphodiesterases (PDE), involved in the regulation of lipolysis in adipocytes and liver.

In vitro mechanistic studies have provided evidence that polyphenols from the bergamot can alter the function of AMPK and pancreatic cholesterol ester hydrolase (pCEH).

4.3 Pancreatic Cholesterol Ester Hydrolase (pCEH) Inhibition

Pancreatic cholesterol ester hydrolase (pCEH) represents an additional target in disrupting cholesterol synthesis. This enzyme catalyzes the hydrolysis of sterol esters into sterols and fatty acids. Disruption of this reaction can significantly improve the serum lipid profile in hyperlipidemic patients. In-vivo data in rats receiving bergamot polyphenol fraction showed inhibition of pCEH activity, although this mechanism has not been directly ascribed to isolated melitidin.

4.4 Additional Multi-Target Mechanisms

Bergamot polyphenolic fraction has been demonstrated to improve lipid metabolism by different mechanisms of action: inhibition of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (naringin, brutieridin, and melitidin), modulation of expression and activity of acyl-CoA oxidase, stearoyl-CoA desaturase 1, and liver-fatty acid binding protein (flavolignans), inhibition of acyl CoA:cholesterol O-acyltransferase (naringin, hesperidin), binding of biliary salts, and improving faecal excretion of sterols.

Certain polyphenols can also act as HMG-CoA reductase inhibitors, thereby mimicking statin action. In addition, flavonoids bind and act as natural inhibitors of quinone oxidoreductase 2 (QR2/NQO2) and other enzymes with potential roles in metabolic regulation.

4.5 Antioxidant Activity

Citrus flavonoids — the class to which melitidin belongs — scavenge free radicals, improve glucose tolerance and insulin sensitivity, modulate lipid metabolism and adipocyte differentiation, suppress inflammation and apoptosis, and improve endothelial dysfunction.

4.6 Antitussive Activity

Melitidin showed a good antitussive effect on cough induced by citric acid in guinea pigs, suggesting that it is a contributor to the antitussive effect of C. grandis 'Tomentosa'. This is the only direct, isolate-specific pharmacological activity reported in peer-reviewed literature for melitidin as a distinct compound (as opposed to its activity within complex bergamot extracts).

5. Scientific Evidence by Area of Use

Important methodological note: The overwhelming majority of clinical studies involving melitidin have used complex standardized bergamot polyphenolic fractions (BPF) containing multiple bioactive compounds simultaneously, including brutieridin, neoeriocitrin, naringin, and neohesperidin. Much of the direct evidence stems from studies on bergamot polyphenolic fractions as a whole, rather than isolated melitidin. Melitidin's individual contribution to observed clinical outcomes cannot be disentangled from these complex mixtures based on currently available evidence.

5.1 Cardiovascular Health: Lipid Profile

Evidence level: Multiple randomized controlled trials on bergamot BPF; preliminary/indirect for melitidin in isolation.

Multiple clinical trials have provided evidence that different forms of orally administered bergamot can reduce total cholesterol and low-density lipoprotein cholesterol.

A key RCT published in Frontiers in Pharmacology (Toth et al., 2015) followed subjects with moderate hypercholesterolemia for 6 months: Bergamot was shown to reduce plasma lipids, atherogenic small dense LDL, and subclinical atherosclerosis in subjects with moderate hypercholesterolemia in a 6-month prospective study.

A randomized double-blind placebo-controlled study evaluated bergamot polyphenol fraction for lowering hyperlipidemia: The study evaluated bergamot polyphenol fraction in patients randomized into three groups: (1) placebo (n=20), (2) bergamot polyphenol fraction (n=20), and (3) a bergamot polyphenol fraction phytosomal formulation (n=20).

A 2024 RCT published in PMC11174436 assessed a combined bergamot and artichoke nutraceutical: The aim was to assess whether dietary supplementation with a nutraceutical blend comprising extracts of bergamot and artichoke — both standardized in their characteristic polyphenolic fractions — could positively affect serum lipid concentration and insulin sensitivity, hs-CRP, and indexes of non-alcoholic fatty liver disease (NAFLD) in 90 healthy individuals with suboptimal cholesterol levels. After 6 weeks, the active-treated group experienced significant improvements in levels of triglycerides (TG), apolipoprotein B-100 (Apo B-100), and apolipoprotein AI (Apo AI) versus baseline.

A 2-month randomized placebo-controlled trial assessed bergamot phytosome combined with artichoke leaf extract: The study evaluated 600 mg of bergamot phytosome® (from Citrus bergamia Risso) combined with 100 mg of artichoke leaf standardized dry extract (from Cynara cardunculus L.) in patients with mild hypercholesterolemia who were poor responders to bergamot alone. Sixty overweight adults were randomized into two groups: 30 supplemented and 30 placebo. Between the two groups, total and LDL cholesterol in the supplemented group (compared to placebo) showed significant decreases over time.

An open-label parallel-group study also compared bergamot BPF with rosuvastatin: This study involved 77 human subjects with elevated LDL and triglycerides, administered placebo (n=15), rosuvastatin 10 mg (n=16), rosuvastatin 20 mg (n=16), bergamot polyphenol fraction BPF (n=15), or bergamot polyphenol fraction with rosuvastatin (n=15). The total duration was 30 days.

Taken together, the clinical signal for bergamot polyphenolic fractions (containing melitidin) on lipid parameters is consistent, but study sizes are generally small, and most trials do not include long-term follow-up. Large-scale, long-term clinical studies specifically investigating melitidin are still lacking.

5.2 Metabolic Health: Blood Glucose and Insulin Sensitivity

Evidence level: Preliminary; derived from bergamot fraction studies, not isolated melitidin.

A randomized, double-blind, placebo-controlled study was carried out in 60 patients suffering from type 2 diabetes mellitus and mixed hyperlipemia. The pharmacological treatment of dyslipidemia in patients undergoing type 2 DM by means of statins is accompanied by relevant side effects, and oral supplementation with natural antioxidants, such as Citrus polyphenols, has been suggested to improve cardioprotection in such patients.

Bergamot flavonoids seem to positively impact fat and sugar metabolism, while also activating AMP kinase (AMPK), which is an enzyme involved in glucose and fatty acid metabolism. Bergamot is also able to improve insulin sensitivity, which increases the body's ability to use glucose, thus potentially lowering blood sugar. These findings are largely derived from in-vitro mechanistic studies and small-scale clinical observations; robust clinical trials isolating melitidin's effect on glycemic parameters have not been published.

5.3 Liver Health: Non-Alcoholic Fatty Liver Disease (NAFLD)

Evidence level: Preliminary, based on one RCT using a bergamot combination product.

A total of 102 patients with liver steatosis were enrolled in a double-blind, placebo-controlled clinical trial. The intervention group received a nutraceutical containing a bergamot polyphenol fraction and Cynara Cardunculus extract, 300 mg/day for 12 weeks. The control group received a placebo daily. Liver fat content (by transient elastography), serum transaminases, lipids, and glucose were measured at baseline and the end of the study.

Results found a greater liver fat content reduction in participants taking the nutraceutical rather than placebo (−48.2 ± 39 vs. −26.9 ± 43 dB/m, p = 0.02); the percentage CAP score reduction was statistically significant in those with android obesity, overweight/obesity, and in women. Notably, this trial used a combination product (bergamot + wild cardoon), making attribution to melitidin specifically impossible.

5.4 Antitussive / Respiratory Activity

Evidence level: Animal (preclinical) only.

Researchers reported the isolation and structural characterization of a newly found flavonoid, named melitidin, from Citrus grandis 'Tomentosa', and examined its antitussive activity — the traditional indication of this plant. Melitidin inhibited citric acid-induced cough in guinea pigs, indicating that melitidin is a contributor to the antitussive effect of C. grandis 'Tomentosa'. No human clinical trials investigating melitidin's antitussive effects have been published.

5.5 Antioxidant and Anti-Inflammatory Activity

Evidence level: In vitro and mechanistic; limited human data.

A study comparing qualitative and semi-quantitative profiles of polyphenol fractions from bergamot leaf and fruit evaluated their antioxidant and anti-inflammatory activity using LC-ESI/MS with targeted, semi-targeted, and untargeted analytical approaches. A total of 108 compounds were identified, 100 of which were present in both the leaf and fruit extracts.

Citrus bergamot flavonoids have general anti-inflammatory properties and antioxidant effects, as evidenced by the reduction in C-reactive protein and other inflammatory markers. Although citrus flavonoids exert multiple beneficial effects, their mechanisms of action are not completely established.

5.6 Statin-Intolerant Populations

Statins are widely used for their cholesterol-lowering properties; however, they are not universally well tolerated, suggesting there is a need to identify novel cholesterol-lowering strategies. Early clinical trials along with mechanistic studies suggest that bergamot (and by extension, melitidin-containing fractions) can reduce total cholesterol and LDL-C through mechanisms that are distinct from current pharmaceutical approaches.

An open-label study in patients on second-generation antipsychotics (who often develop drug-induced dyslipidemia) assessed a low-dose BPF regimen: At the end of the trial only nine patients (37.5%) reached a minimal LDL reduction according to current statin guidelines, whereas no patients experienced an LDL reduction ≥50%. BPF adjunctive treatment was well tolerated at 500 mg/day dosage, as shown by the lack of pharmacokinetic effects on haematic concentrations of antipsychotics, and by the dropout causes, all unrelated to adverse and/or unwanted events. This trial highlights both the limited efficacy at lower doses in this specific population, and the consistent tolerability data.

6. Body Systems and Health Areas

Cardiovascular system: Citrus flavonoids scavenge free radicals, improve glucose tolerance and insulin sensitivity, modulate lipid metabolism and adipocyte differentiation, suppress inflammation and apoptosis, and improve endothelial dysfunction. The intake of citrus flavonoids has been associated with improved cardiovascular outcomes.
Hepatic (Liver) system: Bergamot BPF, containing melitidin, has been studied for its effect on liver steatosis and liver enzyme markers in RCT settings, with a 12-week trial showing statistically significant reductions in liver fat content.
Metabolic / Endocrine system: The anti-diabetic and dyslipidemia-correcting effects of bergamot polyphenols may be explained by their ability to activate AMPK — a central regulator of glucose and fatty acid metabolism — and to inhibit cAMP phosphodiesterases (PDE) involved in the regulation of lipolysis in adipocytes and liver.
Respiratory system: Citrus grandis 'Tomentosa', which contains melitidin, is a traditional Chinese medicine recorded in the Pharmacopoeia of the People's Republic of China for preventing cough and dissipating phlegm.
Antioxidant defense: Melitidin contributes to the overall antioxidant capacity of bergamot and pummelo extracts, as measured by ORAC and cellular antioxidant activity assays.

7. Dosage Forms and Dosages Reported in Studies

No established, standardized dosage for isolated melitidin exists in the published clinical literature, as all human trials have used complex bergamot polyphenolic fractions. The following dosages have been reported in clinical studies of bergamot preparations containing melitidin:

After successful trials in a rat model, researchers investigated the effect of brutieridin and melitidin-containing BPF in human patients with high LDL and high triglyceride levels. Patients who received 500 mg or 1,000 mg of BPF for 30 consecutive days saw significant reductions in total cholesterol and related markers.
A randomized double-blind placebo-controlled study of bergamot polyphenol fraction enrolled patients into three groups: placebo (n=20), bergamot polyphenol fraction (n=20), and bergamot polyphenol fraction phytosomal formulation (n=20).
In a liver steatosis trial, the intervention group received a nutraceutical containing a bergamot polyphenol fraction and Cynara Cardunculus extract, 300 mg/day for 12 weeks.
A randomized placebo-controlled trial investigated whether 600 mg of bergamot phytosome® combined with 100 mg of artichoke leaf standardized dry extract could be an alternative in patients with mild hypercholesterolemia who were poor responders to bergamot.
BPF adjunctive treatment was studied at 500 mg/day dosage in patients on antipsychotic medications and was found to be well tolerated.

8. Safety Considerations

8.1 General Tolerability

The use of bergamot in multiple clinical trials has consistently shown that it is well tolerated in studies ranging from 30 days to 12 weeks. No serious adverse events specifically attributable to melitidin in isolation have been reported in the peer-reviewed literature, partly because melitidin has never been the sole active ingredient in a human study.

8.2 Pharmacokinetics and Bioavailability

Despite encouraging preclinical and clinical data, pharmacokinetic information on bergamot flavonoids in humans remains limited. Like other citrus flavonoids, these compounds are thought to undergo intestinal and hepatic metabolism, with glucuronidation and sulfation likely affecting their bioavailability.

Pharmacokinetic studies indicate that citrus flavonoids largely bypass absorption in the upper gastrointestinal tract, reaching the colon where they are deglycosylated by the gut microbiota. The resulting aglycone metabolites are absorbed by enterocytes, while residual glycosides undergo fermentation to produce short-chain fatty acids (SCFAs).

The level of parent flavanones in plasma is negligible. The major reason is that although flavanones are absorbed into enterocytes after oral intake, they are rapidly metabolized — in particular, into conjugates, sulfates, and glucuronides, which are the major forms circulating in plasma.

Citrus flavonoids are well-known for their beneficial effects at the cardiovascular and cardiometabolic level, but often the encouraging in vitro results are not confirmed by in vivo approaches, and clinical trials are also inconsistent. Their limited bioavailability can be, at least in part, the reason for these discrepancies. Phytosomal formulations of bergamot BPF have been developed specifically to address this issue.

8.3 Absence of Isolated Safety Data

Large-scale, long-term clinical studies specifically investigating melitidin are still lacking. While melitidin appears to be a promising contributor to the health benefits associated with bergamot, more research is needed to conclusively validate its efficacy and safety as a stand-alone ingredient.

8.4 Drug Interaction Considerations

No specific drug interaction data for isolated melitidin have been reported in peer-reviewed sources. The compound's structural similarity to statins raises the theoretical question of additive lipid-lowering effects when co-administered with pharmaceutical HMGCR inhibitors, but this has not been formally studied for melitidin specifically. Citrus flavonoids as a class are known to modulate certain cytochrome P450 enzymes (particularly CYP3A4), which could theoretically affect the metabolism of co-administered drugs; however, no such interaction data specific to melitidin in isolation are available in the published literature.

9. Current Research Status and Future Directions

The acylated flavonoid glycoside melitidin is being actively developed as an anti-cholesterol statin drug candidate. HMG-CoA reductase enzyme inhibition assays showed that melitidin may be an effective anti-cholesterol statin drug candidate.

The established biosynthetic pathway for melitidin provides genetic resources for the breeding and genetic improvement of pummelo aimed at fortifying the content of biologically active metabolites, opening avenues for agronomic enhancement of melitidin-rich citrus cultivars. The mechanistic debate regarding whether melitidin and its related compounds act principally through direct HMGCR inhibition, AMPK activation, pCEH disruption, or some combination of these and additional targets remains unresolved and represents an active area of investigation.

Further studies and clinical trials to assess the efficacy and to explore the underlying mechanisms of action of citrus flavonoids, including melitidin, are recommended.

References

Health Conditions

Health conditions that Melitidine may help support.

No conditions available.

Body Systems

Body systems that Melitidine may help support.

No body systems available.